INCY News - Candlesense

Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Present at Upcoming Investor Conferences

2 days ago

Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis

Is there any indication that the departure is related to strategic shifts, such as restructuring, M&A activity, or partnership negotiations? Will the loss of the CFO affect investor sentiment or trigger any short‑term volatility in the stock? What impact, if any, might this have on Incyte’s credit facilities, loan covenants, or financing alternatives?

Management

15 days ago

Read more businesswire

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic ...

Fda approval

2 months ago

Read more businesswire

Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

Clinical trials

2 months ago

Read more businesswire

Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

WILMINGTON, Del.--(BUSINESS WIRE)--Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

Clinical

2 months ago

Read more businesswire